A randomized double-blind placebo-controlled first-in-man single-dose and multiple dose study to evaluate the safety, tolerability and efficacy of a recombinant chimeric bacteriophage endolysin HY-133 with an extended phase to evaluate effects of the nasal microbiome

2023-507737-17-00 Protocol HY-133 Human pharmacology (Phase I) - First administration to humans Ongoing, recruiting

Start 10 Jul 2024 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol HY-133

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ongoing, recruiting
Participants planned 52
Countries 1
Sites 1

Nasal colonization with methicillin-susceptible Staphylococcus aureus (MSSA)

Key facts

Sponsor
Universitaetsklinikum Tuebingen AöR
Participant type
Healthy volunteers
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Bacterial Infections and Mycoses [C01]
Trial duration
10 Jul 2024 → ongoing
Decision date (initial)
2024-03-28
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Nasal colonization with methicillin-susceptible Staphylococcus aureus (MSSA)

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Universitaetsklinikum Tuebingen AöR

Sponsor organisation
Universitaetsklinikum Tuebingen AöR
Address
Geissweg 3, Innenstadt Innenstadt
City
Tübingen
Postcode
72076
Country
Germany

Scientific contact point

Organisation
Universitaetsklinikum Tuebingen AöR
Contact name
Sebastian Volc

Public contact point

Organisation
Universitaetsklinikum Tuebingen AöR
Contact name
Sebastian Volc

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ongoing, recruiting 52 1
Rest of world 0

Investigational sites

Germany

1 site · Ongoing, recruiting
Universitaetsklinikum Tuebingen AöR
Department of Dermatology, Liebermeisterstrasse 25, Innenstadt, Tuebingen

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2024-07-10 2024-08-13

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-01-31 Germany Acceptable
2024-03-28
2024-03-28
2 NON SUBSTANTIAL MODIFICATION NSM-1 2024-05-15 Germany Acceptable
2024-03-28
2024-05-15
3 NON SUBSTANTIAL MODIFICATION NSM-2 2025-10-01 Germany Acceptable
2024-03-28
2025-10-01
4 SUBSTANTIAL MODIFICATION SM-2 2025-10-30 Germany Acceptable
2025-11-28
2025-12-03